| Business

Become a contributor

Bookmark Econotimes

| Business

Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market

Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro

Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure

Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch

Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares

Bain Capital Moves to Acquire Majority Stake in Echo Marketing

Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies

Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades

Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026

SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round

Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle

Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up

Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026

Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms

Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel

Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions

Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety

©Econometrics LLC . All Rights Reserved.

Vical to Provide Company Update at BIO Asia International Conference

Thursday, March 9, 2017 12:00 PM UTC

SAN DIEGO, March 09, 2017 -- Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook at 10:45 a.m. JST on Tuesday, March 14, at the Biotechnology Innovation Organization (BIO) Asia International Conference (Tokyo – March 14-15). A copy of the presentation will be available through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.

About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com.

Tony Ramos
(858) 646-1127
Website: www.vical.com

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Market Data

Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up

Zohran Mamdani Sworn In as New York City Mayor in Historic New Year Ceremony

U.S. Dollar Starts 2026 Weak as Yen, Euro and Sterling Hold Firm Amid Rate Cut Expectations

Xi Jinping to Host South Korean President Lee Jae Myung as China Seeks to Strengthen Seoul Ties

Russia and Ukraine Trade Accusations Over New Year Attacks as Peace Talks Intensify

Citi Forecasts a Volatile but Ongoing Bull Market for S&P 500 in 2026

Singapore GDP Growth Surges in 2025 but Outlook Remains Cautious Amid Global Trade Risks

Bolsonaro Discharged From Hospital and Transferred to Prison After Medical Treatment

South Korea Factory Activity Returns to Growth in December on Export Rebound

EconoTimes

Disclaimer: EconoTimes provides references and links to selected blogs and other sources of economic and market information as an educational service to its clients and prospects and does not endorse the opinions or recommendations of the blogs or other sources of information. Clients and prospects are advised to carefully consider the opinions and analysis offered in the blogs or other information sources in the context of the client or prospect's individual analysis and decision making. None of the blogs or other sources of information is to be considered as constituting a track record. Past performance is no guarantee of future results and EconoTimes specifically advises clients and prospects to carefully review all claims and representations made by advisors, bloggers, money managers and system vendors before investing any funds or opening an account with any Brokerage. Any news, opinions, research, data, or other information contained within this website is provided as general market commentary and does not constitute investment or trading advice. EconoTimes expressly disclaims any liability for any lost principal or profits without limitation which may arise directly or indirectly from the use of or reliance on such information. As with all such advisory services, past results are never a guarantee of future results.

Vical to Provide Company Update at BIO Asia International Conference

Editor's Picks

Welcome to EconoTimes